PharmaFocus Today – Page 157 – media

myTomorrows and brainstrust partner to support patients living with brain cancer

myTomorrows has announced a new partnership with a UK-based charity, brainstrust, to support individuals living with brain cancer. The partnership will help equip patients with knowledge of relevant treatment options, participation in clinical trials and access to pre-approved drugs, while supporting clinicians when recruiting patients to relevant clinical trials. Brain tumours affect around 80,000 people in England, with only 12% of patients surviving beyond five years of their diagnosis. As part of the agreement, the charity will provide its patient network with timely, up-to-date and useful information surrounding credible and accessible clinical trials, along with myTomorrow’s expertise and support. In addition, myTomorrow’s trained patient navigators will play a key role as a single point of contact to help guide patients with brain tumours and their loved ones, as well as healthcare professionals, through medical care and help them make the best decisions during their treatment journey. Using a GDPR-compliant ISO ...
- Source: drugdu
- 124
- April 8, 2024
Key mechanism controlling bone marrow stem cells could lead to new therapies

Researchers from King’s College London’s (KCL) Comprehensive Cancer Centre have identified a key mechanism that governs how bone marrow stem cells work, which could potentially lead to new therapeutic pathways. The findings from the study will help researchers further understand the key principles involved in stem cell biology and could provide new avenues for the development of efficient stem cell therapeutics. Researchers identified two molecules, Hoxa9 and b-catenin, that control when bone marrow stem cells rest and recover, as well as when they act and replicate. Both molecules work together to control a rare population of self-renewing stem cells that are predominantly found in bone marrow, known as haematopoietic stem cells (HSCs). HSCs are protected from environmental stressors and prevent exhaustion by resting, while inactive HSCs must become active again, replicating themselves by turning into different blood cells, including red blood cells, white blood cells and platelets, to replenish the ...
- Source: drugdu
- 135
- April 8, 2024
RemeGen’s Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren’s Syndrome

YANTAI, China, April 3, 2024 /PRNewswire/ — RemeGen Co. Ltd. (“RemeGen” or “the Company”) (9995.HK, 688331.SH), a commercial-stage biotechnology company, obtained Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) recently for its innovative BLyS/APRIL dual-target fusion protein drug, Telitacicept (RC18), independently developed by RemeGen for the treatment of patients with primary Sjögren’s syndrome (pSS). The FDA grants FTD to accelerate the development and review of new drugs that have the potential to treat life-threatening conditions and address unmet medical needs. Primary Sjögren’s syndrome (pSS) is a common rheumatic disease characterized by autoimmune exocrinopathy that clinically manifests as dry eyes and mouth caused by glandular dysfunction as a result of autoimmune damage with multiple organ systems also at risk of being affected. Studies have shown that B-cells are key immune cells involved in the pathogenesis of pSS, and excessive activation of B-cells is a pathogenic indicator ...
- Source: drugdu
- 165
- April 8, 2024
Hengrui’s Innovative Drug Fluzoparib Alone or in Combination with Apatinib HER2 Negative Breast Cancer Indication Included in Breakthrough Therapy Variety

Recently, Hengrui Pharmaceuticals’ innovative drug fluazoparib (Errayi®) alone or in combination with apatinib (Etan®) for the treatment of HER2-negative breast cancer with mutations in the germline breast cancer susceptibility gene (gBRCA) has been included in the list of breakthrough therapeutic varieties by the Center for Drug Evaluation of the State Drug Administration (CDEA). According to the data released by the International Agency for Research on Cancer (IARC) of the World Health Organization in 2020, breast cancer has become the world’s number one malignant tumor and is one of the most common malignant tumors in women. Currently, the incidence of breast cancer in domestic patients is growing rapidly and has been ranked first on the spectrum of female tumor incidence, and recurrence and metastasis occur in nearly 50% of patients after treatment. Human breast cancer susceptibility genes (BRCA) are important oncogenes in the human body, including BRCA1 and BRCA2. Compared with ...
- Source: drugdu
- 181
- April 8, 2024
Profound Medical, Siemens Healthineers collab on ultrasound ablation

BY SEAN WHOOLEY The TULSA-PRO system from Profound Medical. [Image from Siemens Healthineers]Profound Medical (Nasdaq:PROF) announced today that it entered into a non-exclusive collaboration with Siemens Healthineers. The two companies aim to lay the groundwork for Profound to begin marketing a complete therapeutics solution. They want to combine the Profound TULSA-PRO system with the Siemens Magnetom Free.Max magnetic resonance (MR) scanner. While this combination falls under the remit of Profound’s own sales force, the company also plan to market TULSA-PRO as a standalone offering. This enables customers to use the technology with the MR hardware of their choice. TULSA-PRO performs the company’s transurethral ultrasound ablation (TULSA) procedure. It employs real-time MR guidance for precision while killing targeted prostate tissue through sound absorption technology. The system enables surgeons to ablate whole- or partial-gland prostate tissue in patients with low- intermediate- or high-risk prostate cancer. It also treats benign prostatic hyperplasia (BPH). ...
- Source: drugdu
- 97
- April 7, 2024
Bessel launches accelerator program for medtech startups

BY JIM HAMMERAND Bessel and an Alabama tech hub today said they are launching Hatch Powered by Bessel, an accelerator program for medtech startups. Applications are now open for the 10-week program, which starts in Fairhope, Alabama, this summer. The accelerator “combines the passion of startup founders, the guidance of seasoned medical device experts, and the burgeoning startup ecosystem and investment in Alabama,” Bessel said in a news release. “… The program aims to equip medtech startups to create sustainable and scalable innovations—breakthroughs that scale—and to give founders the entrepreneurial resource ecosystem they need for long-term success.” Startups selected for the program will receive a travel stipend, access to events and workshops, and guidance on strategy, fundraising and execution from lifescience industry entrepreneurs who will act as mentors and advisors. The startups may be offered funding for equity by Hatch Fairhope after the cohort concludes with finale events in Fairhope, ...
- Source: drugdu
- 152
- April 7, 2024
Cambridge researchers begin new trial for oesophageal cancer screening

Researchers at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge have announced the launch of the BEST4 trial to evaluate a capsule sponge test to prevent oesophageal cancer. Funded by Cancer Research UK and the National Institute for Health and Research, the capsule sponge could see routine screening introduced into the NHS if successful. Responsible for around 9,200 new cases every year in the UK, oesophageal cancer occurs in the long, hollow tube that runs from the throat to the stomach, known as the oesophagus. The BEST4 trial, launched at Addenbrooke’s Hospital, is investigating whether the pill-on-a-thread test can be used to screen or monitor those most at risk of the disease. The ten-minute test is used for Barrett’s oesophagus, sometimes called a pre-cancerous condition, which is usually identified via an endoscopy and a biopsy at a hospital, following a GP referral. The process is time-consuming, unpleasant ...
- Source: drugdu
- 93
- April 7, 2024
Kanabo and City Dock Pharmacy team up

Kanabo Group has linked up with City Dock Pharmacy in London, to introduce a walk-in pain clinic offering specialised medicines, including medicinal cannabis. The partnership will cater for patients who are eligible for alternative therapies, as traditional treatments have not delivered improvements. The facility, which will be situated at City Dock Pharmacy in Wapping, will deliver both walk-in and appointment-related services, and becomes the UK’s first walk-in clinic for pain management. The clinic will represent an extension of Kanabo’s ‘Treat It’ online platform, allowing onsite pharmacists will also be able to guide patients through the medicinal cannabis treatment options. Meanwhile, the clinic will also support the unrolling of personalised plans for the growing number of chronic pain sufferers across the UK. At present, such individuals often face difficulties accessing medical treatments due to long waiting times and affordability. The latest development is part of Kanabo’s wider ambition to extend its ...
- Source: drugdu
- 93
- April 7, 2024
CellVoyant secures £7.6 million AI stem cell boost

CellVoyant – an AI biotechnology spin-out from the University of Bristol – has announced a £7.6 million funding round. Led by Octopus Ventures – with additional participation from Horizons Ventures, Air Street Capital and Verve Ventures – the funding represents the first stage in commercialising CellVoyant’s first of its kind AI and imaging platforms. Meanwhile, the company now aims to enable the rapid development of novel cell therapies. Stem cells unlock a wide range of treatment possibilities that have not historically been available to patients. Indeed, current treatments tend to act on the body’s existing cells, while stem cells have the potential to develop into different cell types in the body – replacing dysfunctional cells or regenerating damaged tissues and organs. CellVoyant’s platform combines advanced AI with live cell imaging to address pain points. The technology can extract spatial and temporal information in real-time from hundreds of millions of cells. ...
- Source: drugdu
- 122
- April 7, 2024
Aston University receives £10m for membrane institute

Aston University is on course to create the Aston Institute for Membrane Excellence (AIME) – a cross-disciplinary facility to develop novel biomimetic membranes – having received £10m from Research England. The institute will be led by Professor Roslyn Bill, from the School of Biosciences, along with Professor Paul Topham from the department of Chemical Engineering and Applied Chemistry. Both biological and synthetic membranes are significant across several many sectors. Indeed, the world’s top ten selling human medicines all target proteins in biological membranes, while synthetic polymer membranes are commonly used in the water purification industry. The AIME believes that the full potential of membranes will only be realised by an interdisciplinary group which spans biology, physics and chemistry and that can investigate membranes holistically. Professor Bill, a European Research Council (ERC) Advanced grantee leads Aston Membrane Proteins and Lipids (AMPL) research centre of excellence that studies the structure and function ...
- Source: drugdu
- 166
- April 7, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.